后疫情时代急性肢体缺血介入策略与结局的范式转变
基于TriNetX全球研究网络、覆盖4国80家医疗机构的多中心查询,倾向性评分匹配后比较COVID前(2017-2019)与COVID期(2020-2022)各7344例急性肢体缺血患者,COVID期30天死亡风险更高(RR=1.211,p=0.027),机械取栓使用更多(RR=1.314,p<0.0001),机械取栓较开放血管重建需更多再干预但无死亡和保肢后果差异。
要点
- COVID期急性肢体缺血患者30天死亡风险高于COVID前(RR=1.211,p=0.027)。
- COVID期机械取栓使用较COVID前增多(RR=1.314,p<0.0001)。
- 机械取栓较开放血管重建30天再干预更多,但死亡和保肢无相关后果。
核心结论
- 近3年观察到向基于机械取栓策略的显著转变,机械取栓较开放血管重建需更多30天再干预,但无死亡和保肢的相关后果。
- COVID期患者死亡率增加可用就诊延迟及与早期COVID波次相关的血栓形成或炎症机制解释。
- 需要更多研究以确定最佳治疗算法。
研究设计与样本
- 使用TriNetX全球研究网络,对4国80家医疗机构中接受急性肢体缺血治疗的患者进行多中心查询。
- 采用倾向性评分匹配以校正合并症,比较COVID前(2017-2019)与COVID期(2020-2022)两个时代。
- 计算每个时代30天内不良结局风险,包括再干预(RI30)、大/小截肢和死亡;并按初始干预分层:开放血管重建(OR)、机械取栓(MT)或单纯导管导向溶栓及辅助血管内操作(CDT/EP)。
- 倾向性评分匹配后,COVID前时代和COVID时代队列各纳入7344例患者。
主要发现
- COVID期患者30天死亡风险较COVID前时代更高(RR=1.211,p=0.027)。
- COVID期机械取栓干预较COVID前时代更频繁(RR=1.314,p<0.0001)。
- MT患者较OR患者需要更多RI30(COVID前:RR=2.074,p=0.006;COVID期:RR=1.600,p=0.025)。
- OR患者较CDT/EP患者30天死亡率更高(COVID前:RR=2.368,p<0.0001;COVID期:RR=2.013,p<0.0001),大截肢率也更高(COVID前:RR=2.432,p<0.0001;COVID期:RR=2.176,p<0.0001)。
- COVID前CDT/EP患者较OR患者RI30风险更高(RR=1.449,p=0.005),小截肢风险也更高(RR=1.500,p=0.010)。
临床怎么用
- 作者认为,在选择介入策略前必须仔细考虑合并症危险因素和缺血严重程度,以预防不良结局并最大化保肢。
- 作者指出,开放血管重建策略与单纯溶栓治疗相比与死亡和肢体丢失增加相关。
- 作者指出,基于机械取栓的方法近3年使用越来越多,接受MT的患者更可能需要在30天内再干预。
局限性
- 需要更多研究以确定最佳治疗算法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We performed a large-scale comparison of patients treated for acute limb ischemia (ALI) in the pre-COVID (2017-2019) and COVID (2020-2022) eras to evaluate changes in interventional strategies and compare factors associated with adverse outcomes. We sought to characterize patient outcomes in an evolving ALI treatment algorithm in response to pandemic-associated presentation delays and rapid technological advancements in mechanical thrombectomy (MT). METHODS: Using the TriNetX global research network, we conducted a multicenter query across 80 health care organizations (HCOs) spanning 4 countries for patients treated for ALI. Propensity score matching was performed to account for comorbidities. Risk of adverse outcomes within 30 days was calculated for each era, including re-intervention (RI30), major/minor amputation, and death. Patients were then stratified by initial intervention: open revascularization (OR), MT, or catheter-directed thrombolysis and adjunctive endovascular procedures alone (CDT/EP). Risk of adverse outcomes was compared between treatment groups of the same era. RESULTS: After propensity score matching, the pre-COVID era and COVID era cohorts included 7344 patients each. COVID era patients experienced a statistically significant higher risk of 30-day mortality (RR=1.211, p=0.027). Mechanical thrombectomy interventions were performed more frequently in the COVID era (RR=1.314, p<0.0001). Comparing outcomes between treatment groups, MT patients required RI30 more than OR patients (pre-COVID: RR=2.074, p=0.006; COVID: RR=1.600, p=0.025). Open revascularization patients had higher 30-day mortality (pre-COVID: RR=2.368, p<0.0001; COVID: RR=2.013, p<0.0001) and major amputations (pre-COVID: RR=2.432, p<0.0001; COVID: RR=2.176, p<0.0001) than CDT/EP. Pre-COVID CDT/EP patients were at higher risk for RI30 (RR=1.449, p=0.005) and minor amputations (RR=1.500, p=0.010) than OR. The MT group had higher major amputation rates than CDT/EP (pre-COVID: RR=2.043, p=0.019; COVID: RR=1.914, p=0.007). COVID-era MT patients had greater 30-day mortality (RR=1.706, p=0.031) and RI30 (RR=1.544, p=0.029) than CDT/EP. CONCLUSION: Significant shifts toward an MT-based approach have been observed in the last 3 years. Although MT required more RI30 than OR, there was no associated consequence of mortality and limb salvage. The increased mortality seen among COVID-era patients could be explained by delayed presentation, as well as poorly understood pro-thrombogenic or pro-inflammatory mechanisms related to the first waves of COVID. More research is necessary to determine an optimal treatment algorithm.Clinical ImpactComorbid risk factors and severity of ischemia must be carefully considered before selecting an interventional strategy to prevent adverse outcomes and maximize limb salvage. Open revascularization strategies are associated with increased mortality and limb loss compared to less-invasive thrombolytic therapy alone. Mechanical thrombectomy (MT)-based approaches have been increasingly used in the last 3 years. Patients receiving MT are more likely to require reintervention within 30 days.
引用
- Wainwright BS, Chihade DB, Costanza MJ, et al. Paradigm Shift of Interventional Strategies and Outcomes for Acute Limb Ischemia Post-Pandemic. J Endovasc Ther. 2024. PMID: 38606923. doi:10.1177/15266028241246162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。